Investigating how cGAS signaling affects DNA damage response
Non-canonical cGAS signaling in DNA damage response
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-10977044
This study is looking at how a protein called cGAS helps our immune system respond to damaged DNA, which could help us learn more about cancer and aging, and hopefully lead to new treatments for these conditions.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-10977044 on ClinicalTrials.gov |
What this research studies
This research explores the role of cyclic-GMP-AMP synthase (cGAS) in the body's immune response to DNA damage. It focuses on how cGAS detects damaged DNA and activates a signaling pathway that influences cell cycle checkpoints and DNA repair mechanisms. By understanding these processes, the research aims to uncover new insights into how DNA damage can lead to conditions like cancer and aging. Patients may benefit from findings that could lead to novel therapeutic strategies targeting DNA damage responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with conditions related to DNA damage, such as certain cancers or genetic disorders affecting DNA repair mechanisms.
Not a fit: Patients with no known issues related to DNA damage or those not experiencing any related health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the body's ability to repair DNA damage, potentially reducing cancer risk and improving outcomes for patients with DNA repair deficiencies.
How similar studies have performed: Other research has shown promising results in understanding the role of cGAS in immune responses and DNA damage, indicating that this approach has potential for significant breakthroughs.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KERUR, NAGARAJ — OHIO STATE UNIVERSITY
- Study coordinator: KERUR, NAGARAJ
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.